Kymera Therapeutics Inc Virtual Immunology R&D Day Transcript
Hello, on behalf of the Kymera team, I'd like to welcome everyone to our Virtual Immunology R&D Day and I'm Justine Koenigsberg, Head of Investor Relations at Kymera. Starting with slide 3, I'd like to remind you that today's presentations will include forward-looking statements about our future expectations, plans, and prospects.
These statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. A description of these risks can be found in our most recent 10-Q filed with the SEC. Any forward-looking statements speak only as of today's date and we assume no obligation to update any forward-looking statements made on today's call.
We have a full agenda today focused on our growing immunology pipeline as shown on slide 4. Nello Mainolfi, our President and CEO will begin today's discussion with an overview of our strategy and the opportunity to revolutionize immunology with small molecule degraders. Then Jared Gollob, Amy Wang, and Juliet Williams will review our IRAK4,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
